Tufts–Medable: AI agents could deliver $21m net benefit per programme in clinical trials
An analysis by Tufts CSDD and Medable says AI agents speed up clinical trials, with a net value of $21 million per programme.
Who is affected and how
- pharmaceuticals
- For the business case, the figure should be recalculated for the company's own programme structure.
Sources
- Medable, Tufts CSDD value AI gain at $21m net per programme - pharmaphorumpharmaphorum.com · Aug 19, 2026 · magyar
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.